Aviva
EGRX

Aviva’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Aviva’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-28,435
Closed -$1.19M – 994
2021
Q1 		$1.19M Sell
28,435
-3,210
-10% -$149K 0.01% 867
2020
Q4 		$1.47M Sell
31,645
-25,655
-45% -$1.2M 0.01% 771
2020
Q3 		$2.43M Buy
57,300
+9,739
+20% +$426K 0.01% 613
2020
Q2 		$2.28M Sell
47,561
-36,882
-44% -$1.84M 0.01% 720
2020
Q1 		$3.88M Buy
+84,443
New +$4.24M 0.03% 472

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Aviva's EGRX Position: Q2 2021 in Review

Aviva sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2021, closing a stake of 28,435 shares — an estimated $1.19M sold.

Aviva first reported a position in EGRX in Q1 2020 and held it in 5 quarters. The position peaked at $3.88M in Q1 2020. 146 funds tracked by Wall St. Rank hold EGRX as of Q2 2021.

  • Aviva reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Aviva sold 28,435 Eagle Pharmaceuticals, Inc. shares in Q2 2021, an estimated $1.19M.
  • Aviva first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2020 and held it in 5 quarters.
  • Aviva's Eagle Pharmaceuticals, Inc. position peaked at $3.88M in Q1 2020.
  • 146 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2021.

Based on Aviva's 13F filing for Q2 2021, filed 10 Aug 2021.